For chromosome 18q11.2‐q12 no‐loss patients with RAS (KRAS and NRAS)/BRAF wildtype tumors and left‐sided location of the primary tumor, anti‐EGFR in the first‐line is a viable alternative, now recommended solely beyond the first‐line.29 Here, BRAF is linked to neoplasm.